Industry Overview

Diagnostic biomarker market was valued at $5.1 billion in 2025 and is projected to reach $38.9 billion by 2035, growing at a CAGR of 22.7% during the forecast period (2026-2035). The market is growing due to the increasing prevalence of chronic diseases like cancer and cardiovascular disorders, the rising demand for personalized medicine, and significant advancements in technology like genomics and AI. Key factors driving this growth include increased investments in R&D, supportive regulatory frameworks, and the expansion of diagnostic applications for early and precise disease detection, especially through non-invasive methods like liquid biopsies.

Market Dynamics

Growing Adoption of Precision Medicine and Companion Diagnostics

One of the most significant drivers of the global diagnostic biomarker market is the rapid transition from generalized treatment approaches to precision medicine. Biomarkers play a foundational role in identifying patient-specific disease characteristics that guide treatment decisions, especially in oncology, neurology and immunology. With pharmaceutical companies increasingly co-developing companion diagnostic tests alongside targeted therapeutics, biomarker-based diagnostics are becoming mandatory for drug eligibility and clinical success. As the number of targeted therapies in the global drug development pipeline continues to rise, the demand for validated and clinically actionable biomarkers accelerates, strengthening market growth.

Technological Advancements in Molecular Biology, Omics, and AI-Based Diagnostics

Continuous innovation in diagnostic technology has significantly improved the speed, sensitivity and scalability of biomarker discovery and validation. Next-generation sequencing (NGS), proteomics, metabolomics, multi-omics integration and high-throughput screening platforms have made it possible to identify complex biomarker signatures that cannot be captured by single-marker assays. The integration of artificial intelligence and machine learning in biomarker data analytics further elevates diagnostic accuracy by enabling pattern recognition across extensive datasets. These technology-driven enhancements are not only expanding the range of measurable biomarkers but are also facilitating broader clinical adoption, including minimally invasive tests such as liquid biopsies.

Rising Global Prevalence of Chronic and Lifestyle-Associated Diseases

The increasing burden of chronic diseases such as cancer, cardiovascular disorders, diabetes, autoimmune diseases and neurodegenerative conditions is significantly strengthening demand for diagnostic biomarker tests. Biomarkers are now frequently used not just for early diagnosis but also for risk assessment, screening, prognosis and monitoring of therapeutic outcomes. With an aging population exhibiting higher susceptibility to chronic illnesses, along with increased awareness of preventive healthcare and screening programs, biomarker-based diagnostics are gaining widespread clinical acceptance. Expanding healthcare access in developing regions further multiplies the testing volume, fueling market growth across both developed and emerging economies.

Market Segmentation

• Based on the application, the market is segmented into oncology, cardiology, neurology, nephrology and others.
• Based on the diagnostic technique, the market is segmented into elisa, colorimetric assay, liquid chromatography-mass spectrometry, and particle-enhanced turbidimetric immunoassay and others.
• Based on the end-user, the market is segmented into hospitals & diagnostic labs and research centers.

Oncology Segment to Grow at a Considerable Market Share

The dominance of oncology biomarkers is primarily driven by the rapidly rising global burden of cancer and the increasing adoption of biomarker-based screening, early disease detection, and personalized treatment planning. Oncology biomarkers are extensively used for applications such as tumor detection, prognosis, drug response prediction, and monitoring of therapeutic outcomes making them indispensable in precision oncology and targeted drug development.

In addition, the surge in liquid biopsy tests, genomic profiling, and companion diagnostics approved alongside targeted anti-cancer therapeutics has significantly accelerated biomarker adoption in oncology compared to cardiology, neurology, nephrology, and other therapeutic areas. Strong R&D investments by pharmaceutical and biotech companies, increasing clinical trials involving predictive and prognostic cancer biomarkers, and supportive regulatory initiatives for accelerated approvals of biomarker-based cancer diagnostics further solidify oncology as the largest and fastest-growing application segment propelling the overall growth of the Global Diagnostic Biomarker Market.

Hospitals & Diagnostic Labs: A Key Segment in Market Growth

Among all the segments in the global diagnostic biomarker market, the hospitals & diagnostic labs end-user segment stands out as the key segment driving market growth due to its critical role in clinical diagnosis, early disease detection, and patient management. Hospitals and diagnostic laboratories are the primary points of care where biomarker-based tests are widely performed for oncology, cardiology, neurology, infectious diseases, and metabolic disorders. The rapidly increasing patient inflow for chronic and lifestyle-related diseases has significantly boosted the adoption of biomarker-enabled diagnostic tools to ensure high-accuracy results, faster turnaround time, and evidence-based treatment planning.

Technological advancements including automated immunoassay analyzers, point-of-care (POC) biomarker testing equipment, and high-throughput molecular diagnostic systems are being rapidly integrated into hospital laboratories to enhance workflow efficiency and diagnostic precision. Furthermore, reimbursement support in developed markets, expansion of hospital laboratory networks in emerging regions, and increased government and private investments in clinical diagnostic infrastructure are further accelerating biomarker uptake. The rising trend of personalized medicine, where biomarker-based tests are essential for therapy selection and monitoring, has strengthened demand within hospital and diagnostic lab settings. As a result, this segment continues to contribute the largest revenue share and is expected to sustain strong growth over the forecast period, making it the dominant driver of market expansion.

Regional Outlook

The global diagnostic biomarker market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global diagnostic biomarker market, holding a major share due to its highly developed healthcare infrastructure, strong biotechnology ecosystem, and rapid adoption of precision medicine. The US has consistently led biomarker research and commercialization due to extensive investments from both government agencies and private pharmaceutical and biotech companies. The National Institutes of Health (NIH), along with programs such as the Cancer Moonshot and the All of Us Research Program, has significantly expanded biomarker discovery platforms, bioinformatics databases, and genomic sequencing capabilities.

Additionally, the presence of major diagnostic test manufacturers and cutting-edge research institutes accelerates the translation of biomarker discoveries into clinically validated diagnostic tests. Hospitals and laboratories across the country have high access to advanced analytical technologies including liquid chromatography-mass spectrometry, ELISA-based assays, and high-throughput sequencing, ensuring rapid test adoption and scalability. Favorable regulatory support from the FDA for companion diagnostics and reimbursement policies for biomarker-based tests further enhance market growth. The increasing prevalence of cancer, cardiovascular disorders, neurodegenerative diseases, and autoimmune conditions has led to a rising demand for early and accurate diagnosis using biomarkers. Combined with strong collaborations between biotech companies and diagnostic developers, the US remains the global leader in biomarker utilization and innovation, maintaining a significant share of the market.

Market Players Outlook

The major companies operating in the global diagnostic biomarker market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In November 2025, Servier India launched an affordable biomarker testing initiative for leukemia and bile duct cancer in partnership with MedGenome and Strand Life Sciences. The program offers customized biomarker tests for Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) at subsidized rates, enhancing access to quality diagnostics. Healthcare professionals in both private and government sectors can utilize this panel, with IDH1 and IDH2 mutation testing provided free in the government sector. This initiative aims to broaden access to molecular testing, which has been limited to urban populations, ensuring timely and accurate diagnoses for more patients across India.
• In August 2025, Aptamer launched a biomarker discovery service aimed at researchers in pharmaceuticals, biotechnology, and diagnostics. This service combines Aptamer's Optimer technology with proteomic analysis for a high-throughput method to identify and validate disease markers. The process distinguishes between healthy and diseased samples using Optimers synthetic oligonucleotides known for their stability and specificity. This dual approach results in the identification of molecular biomarkers and provides aptamers as affinity ligands, offering the potential to pursue other modalities like antibodies. Additionally, the platform can identify biomarkers that enhance strategies like receptor-mediated endocytosis for drug delivery.
• In August 2024, Illumina, Inc. has announced FDA approval for its TruSight Oncology Comprehensive test, the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims. This test assesses over 500 genes from solid tumors, facilitating the identification of immuno-oncology biomarkers or actionable mutations for targeted therapies. It is specifically approved to identify patients with NTRK gene fusions suitable for treatment with Bayer's VITRAKVI and patients with RET fusion-positive NSCLC for Lilly's RETEVMO. Unlike most companion diagnostics focused on single cancer types, this test offers insights across various solid tumor indications.

The Report Covers

• Market value data analysis for 2026 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global diagnostic biomarker market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.